Ver­tex is pulling back on its ge­net­ic med­i­cine re­search, end­ing all work re­lat­ed to ade­no-as­so­ci­at­ed virus­es, ...

Welcome back to Endpoints Weekly, our roundup of the top headlines in biopharma. Earnings season continued this week, with more comments from pharma executives on the potential impact of tariffs ...

SalioGen Therapeutics, led by Ray Tabibiazar, shut down after failing to perfect its bat-derived gene editing technology.

Kura gets $45M from Kyowa Kirin; Pliant cuts 45% staff; AstraZeneca's Breztri succeeds in asthma trials; Otsuka ends ...

The White House’s budget request proposes a nearly $18 billion cut to NIH spending, and nearly $4 billion slashed at the CDC.

Flagship Pioneering has recruited Rahul Kakkar to lead its genetics-based drug discovery startup Quotient Therapeutics.

Aera Therapeutics shifts focus to lipid nanoparticles for T-cell targeting therapy while continuing work on protein ...

FDA delays Cytokinetics' aficamten PDUFA date to Dec 26 after company adds REMS to heart disease drug application; stock down ...

HHS rolled out a new $500 million initiative to develop universal vaccines for 'pandemic-prone' viruses such as influenza and ...

When Siren Biotechnology CEO Nicole Paulk learned last month that top FDA official Peter Marks had resigned, she began ...

Biogen reports Leqembi Alzheimer's drug sales reached $96M in Q1, up from $19M last year, with $52M from US market. Eisai ...

Bristol Myers Squibb closing viral vector site in Libertyville, IL, shifting production to Devens, MA; affects workers from ...